Mativ Holdings, Inc. (MATV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed mixed results: strong EBITDA growth and margin improvement, but flat net sales and challenges in the healthcare vertical. Positive factors include strategic pricing and AI integration plans, yet customer destocking and supply chain issues linger. The Q&A highlighted operational challenges and cautious optimism without precise timelines. Overall, these factors balance out, suggesting a neutral stock price movement in the short term.
Key Financial Performance
Net Sales $480 million, nearly flat year-over-year on an organic basis and down about 1% as reported. Favorable selling prices and currency were offset by lower volume mix.
Adjusted EBITDA $47.5 million, up 28% versus prior year. A favorable price-to-input cost ratio, lower manufacturing expenses, and favorable currency were partially offset by unfavorable volume mix.
Adjusted EBITDA Margin 9.9%, up 220 basis points versus prior year. This represents the strongest Q1 margin performance since the mid-2022 merger.
FAM Net Sales $188 million, increased by more than 2% on an organic basis and up modestly on a reported basis versus prior year. Growth driven by favorable currency and slightly higher selling prices, partially offset by lower volume mix.
FAM Adjusted EBITDA $27 million, increased by 41% year-over-year. Margins of 14.6% improved by 430 basis points. Gains led by a favorable price-to-input cost ratio, lower manufacturing costs, favorable currency, and lower SG&A expenses. Marginally lower volume mix partially offset these benefits.
SAS Net Sales $291 million, down 2% year-over-year. Lower volume mix was partially offset by favorable currency and selling prices. Driven mainly by lower-than-expected health care volumes.
SAS Adjusted EBITDA Roughly $31 million, increased by approximately 16% year-over-year. Margins of 10.5% improved by 160 basis points. Earnings benefited from a favorable price-to-input cost ratio and reduced SG&A expenses, partially offset by lower volume mix.
Free Cash Flow A use of $7 million, improving by more than $22 million versus prior year. This represents the best Q1 performance since the merger in mid-2022. Driven by a year-over-year operating cash flow improvement of more than $16 million due to lower restructuring expenses and capital expenditure timing.
Net Debt Approximately $954 million, representing a slight seasonal uptick as inventory investments were made ahead of increasing Q2 and Q3 production schedules.
Liquidity Roughly $499 million on a reported basis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Specialty Films Commitment: Secured a sizable new commitment for specialty films from a new aerospace customer, showcasing the application of existing process capabilities to grow in adjacent markets.
FAM Sales Pipeline: Material increase in the FAM sales pipeline compared to the previous year, aimed at offsetting sluggish market demand.
Cost-Cutting Initiatives: Achieved nearly $20 million in savings across SG&A, operations, and procurement in 2025, with a 2026 target of $15 million to $20 million on schedule.
Operational Footprint Optimization: Closed an underperforming plant in Wilson, North Carolina, streamlined SKUs, and improved supply chain efficiency.
Debt Refinancing: Refinanced the majority of debt tranches, simplifying the capital structure, reducing the number of bank participants, and enhancing financial flexibility.
Strategic Blueprint: Formalized a new strategic blueprint to focus on high-growth, high-return markets, leveraging the diverse portfolio and aligning resources for sustainable growth.
Pricing Agility: Implemented pricing actions in January and March 2026 to offset raw material inflation, ensuring a favorable price-to-cost ratio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic and Geopolitical Volatility: The company operates in a volatile macroeconomic environment with mixed demand across its portfolio. Recent geopolitical events, such as the Middle East crisis, have heightened input cost inflation, particularly for crude oil-based inputs like polymers, resins, and chemicals. This creates uncertainty in broader market demand and commercial activity.
Healthcare Vertical Demand Weakness: The healthcare segment experienced significant volume weakness due to customer destocking actions and supply chain inefficiencies, including a temporary outage at the Knoxville, Tennessee facility. This poses a challenge to maintaining consistent revenue from this segment.
Input Cost Inflation: Elevated oil and derivative prices have led to increased costs for raw materials, with full-year inflation estimates rising from $20-$25 million to $40-$50 million. This requires continuous pricing adjustments, which may strain customer relationships and operational agility.
Supply Chain Inefficiencies: A temporary outage at the Knoxville, Tennessee facility caused supply chain disruptions, impacting operational efficiency and customer satisfaction.
Demand Softness in Release Liner and Labels Businesses: Demand remains soft in the release liner and labels businesses, which could affect revenue and profitability in these segments.
Debt and Financial Leverage: The company has a high net debt of $954 million and a leverage ratio of 4.1x, which, while slightly improved, remains a significant financial burden. Interest expenses have also increased due to refinancing efforts.
Market Demand Uncertainty: Broader market demand remains uncertain due to indirect impacts of geopolitical events and economic conditions, which could affect the company's ability to achieve its growth objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Cost Savings Target: The company has set a cost savings target of $15 million to $20 million for 2026, which is proceeding on schedule.
Debt Refinancing: In early April, the company refinanced the majority of its debt tranches, simplifying its capital structure, reducing the number of debt tranches, and enhancing financial flexibility. The new facilities have no maturities until late 2029.
Input Cost Inflation: The company expects full-year raw material inflation to be $40 million to $50 million in 2026, up from the initial estimate of $20 million to $25 million. Pricing actions have been implemented to offset these costs.
Q2 2026 Adjusted EBITDA Outlook: Adjusted EBITDA for Q2 2026 is expected to decline by a mid-single-digit percentage compared to the prior year due to lower volumes, particularly in the healthcare business. Growth in films and filtration businesses and cost savings are expected to partially offset this decline.
Strategic Growth Blueprint: The company has formalized a new strategic growth blueprint focusing on high-growth, high-return markets, leveraging its portfolio's integrated value, and advancing go-to-market strategies.
Free Cash Flow Performance: The company aims to build on its strong free cash flow performance from Q1 2026, which was the best since the mid-2022 merger, and expects another year of strong cash flow.
Market Demand and Pricing Agility: The company is monitoring indirect impacts of geopolitical events on market demand and has implemented pricing agility to maintain favorable price-to-cost ratios.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on customer destocking and supply chain inefficiencies within the healthcare vertical, and when conditions are expected to normalize?
A:Shruti Singhal explained that customer destocking actions and a temporary operational outage at the Knoxville, Tennessee plant created challenges. The plant is now fully operational, and normalization is expected in the back half of the year, though no exact timeline was provided. The company is offsetting these challenges with strengths in other areas like European filtration and aerospace films.
Q:Will you continue favorable pricing if input costs rise, and will you reduce prices if costs come down?
A:Scott Minder stated that input cost inflation is expected to remain sticky in 2026 due to disruptions in oil markets caused by the Middle East conflict. The company will take further pricing actions if costs rise and does not anticipate a quick reduction in prices. Pricing is critical for margin management and long-term value creation for customers and shareholders.
Q:What is the expected revenue impact and timeline for the new specialty films commitment in aerospace?
A:Shruti Singhal expressed excitement about the new commitment but could not disclose financial terms or precise timing due to customer confidentiality. The commercial relationship is expected to commence in Q2, with shipments starting later in the second quarter.
Q:How should we think about cash flow cadence for the rest of 2026 given the seasonal working capital build?
A:Scott Minder explained that Q1 is typically the most demanding cash flow period due to seasonal working capital build and prior year's incentive compensation payouts. The company expects stronger cash flow in Q2 and Q3 and plans to invest additional cash in 2026 for growth. Mativ is focused on improving profit margins, working capital efficiency, and capital expenditure discipline.
Q:Should we expect any divestitures of non-core assets as you complete the first phase of the portfolio review?
A:Shruti Singhal stated that the company has taken decisive actions like closing the Wilson, North Carolina plant and aligning R&D resources. While the Board and management will continue to evaluate opportunities, the current portfolio is considered well-positioned for long-term growth. The focus is on operational and financial discipline and top-line growth.
Q:Review of Unclear Management Responses
A:Shruti Singhal avoided providing specific financial terms or precise timing for the aerospace specialty films commitment due to customer confidentiality. Additionally, no exact timeline was given for the normalization of healthcare vertical challenges.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
East conflict
East crisis
Middle East
Scott
action input
basis point
benefit
blueprint
capital allocation
capital structure
chemical
cost inflation
cost ratio
credit facility
currency volume
debt tranche
event market
flow margin
foundation
health care
impact Middle
impact market
increase pricing
line action
macro environment
manufacturing currency
margin cash
material solution
mid merger
oil
phase
portion
pricing action
resource return
volatility
weakness
MATV Transcript
Mativ Holdings, Inc. (MATV) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call showed mixed results: strong EBITDA growth and margin improvement, but flat net sales and challenges in the healthcare vertical. Positive factors include strategic pricing and AI integration plans, yet customer destocking and supply chain issues linger. The Q&A highlighted operational challenges and cautious optimism without precise timelines. Overall, these factors balance out, suggesting a neutral stock price movement in the short term.
Mativ Holdings, Inc. (MATV) Q4 2025 Earnings Call Transcript
Unknown2-19
While the company shows positive signs in adjusted EBITDA growth, cost savings, and reduced net debt, challenges exist in the SAS segment with headwinds in automotive tapes and labels. The cautious optimism expressed for future periods, alongside a lack of specific guidance on new partnerships, balances out the positives. Overall, the sentiment is neutral, reflecting mixed signals and uncertainties in market demand and specific business areas.
Mativ Holdings, Inc. (MATV) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call showed strong financial performance with positive growth in EBITDA, sales, and EPS. Despite uncertainties like tariffs and facility closure, strategic initiatives and cost reductions are on track. Q&A highlighted positive market share gains and operational improvements. Management's optimistic guidance for margin improvement and strategic portfolio review further supports a positive outlook. However, some uncertainty remains due to lack of specific guidance on 2026 margins, but overall sentiment is positive, expecting a stock price increase of 2% to 8% over the next two weeks.
Mativ Holdings, Inc. (MATV) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary shows mixed results: slight sales increase and strong free cash flow, but flat EBITDA growth and reduced SAS EBITDA. The Q&A highlights positive momentum and cost-cutting initiatives but lacks clarity on strategic reviews. The absence of a strong catalyst or significant negative trend suggests a neutral market reaction.
MATV Slides
MATV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
